Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer

Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer

Small molecule protein kinase inhibitors (PKIs) have become an effective strategy for cancer patients. However, hepatotoxicity is a major safety concern of these drugs, since the majority are reported to increase transaminases, and few of them (Idelalisib, Lapatinib, Pazopanib, Pexidartinib, Ponatin...

Full description

Bibliographic Details
Main Authors: Mauro Viganò, Marta La Milia, Maria Vittoria Grassini, Nicola Pugliese, Massimo De Giorgio, Stefano Fagiuoli
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Cancers
Subjects:
cancer
drug-induced liver injury
hepatitis
hepatotoxicity
liver failure
tyrosine kinase inhibitors
Online Access:https://www.mdpi.com/2072-6694/15/6/1766

Internet

https://www.mdpi.com/2072-6694/15/6/1766

Similar Items